DK1855720T3 - Anvendelse af et modificeret poxvirus til hurtig induktion af immunitet mod et poxvirus eller andre smitstoffer - Google Patents

Anvendelse af et modificeret poxvirus til hurtig induktion af immunitet mod et poxvirus eller andre smitstoffer Download PDF

Info

Publication number: DK1855720T3
Authority: DK; Denmark
Prior art keywords: poxvirus; infectives; immunity against; modified; quick input
Prior art date: 2005-02-23

Application number

DK06707039.1T

Other languages

English (en)

Other versions

DK1855720T4 (da

Inventor

Paul Chaplin

Luis Mateo

Original Assignee

Bavarian Nordic As

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-02-23

Filing date

2006-02-17

Publication date

2017-01-16

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34933889&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1855720(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2006-02-17 Application filed by Bavarian Nordic As filed Critical Bavarian Nordic As

2017-01-16 Application granted granted Critical

2017-01-16 Publication of DK1855720T3 publication Critical patent/DK1855720T3/da

2023-07-24 Publication of DK1855720T4 publication Critical patent/DK1855720T4/da

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/275—Poxviridae, e.g. avipoxvirus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/275—Poxviridae, e.g. avipoxvirus
- A61K39/285—Vaccinia virus or variola virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Virology (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Immunology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Microbiology (AREA)
Engineering & Computer Science (AREA)
Mycology (AREA)
Epidemiology (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Bioinformatics & Cheminformatics (AREA)
Biotechnology (AREA)
Biomedical Technology (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
General Engineering & Computer Science (AREA)
Tropical Medicine & Parasitology (AREA)
Pulmonology (AREA)
Plant Pathology (AREA)
Biophysics (AREA)
Physics & Mathematics (AREA)
Biochemistry (AREA)
AIDS & HIV (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

DK06707039.1T 2005-02-23 2006-02-17 Anvendelse af et modificeret poxvirus til hurtig induktion af immunitet mod et poxvirus eller andre smitstoffer DK1855720T4 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP05003873		2005-02-23
PCT/EP2006/001447 WO2006089690A1 (en)	2005-02-23	2006-02-17	Use of a modified poxvirus for the rapid induction of immunity against a poxvirus or other infectious agents

Publications (2)

Publication Number	Publication Date
DK1855720T3 true DK1855720T3 (da)	2017-01-16
DK1855720T4 DK1855720T4 (da)	2023-07-24

Family

ID=34933889

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK06707039.1T DK1855720T4 (da)	2005-02-23	2006-02-17	Anvendelse af et modificeret poxvirus til hurtig induktion af immunitet mod et poxvirus eller andre smitstoffer

Country Status (25)

Country	Link
US (3)	US20110142877A1 (da)
EP (1)	EP1855720B2 (da)
JP (3)	JP2008531489A (da)
KR (1)	KR20070110007A (da)
CN (1)	CN101128217B (da)
AU (1)	AU2006218115B2 (da)
BR (1)	BRPI0608310A2 (da)
CA (1)	CA2593532C (da)
CY (1)	CY1118573T1 (da)
DK (1)	DK1855720T4 (da)
EA (1)	EA013404B1 (da)
ES (1)	ES2608627T5 (da)
FI (1)	FI1855720T4 (da)
HU (1)	HUE030037T2 (da)
IL (1)	IL184347A (da)
LT (1)	LT1855720T (da)
MX (1)	MX2007010158A (da)
MY (1)	MY162027A (da)
NO (1)	NO347468B1 (da)
NZ (1)	NZ556409A (da)
PT (1)	PT1855720T (da)
SI (1)	SI1855720T2 (da)
UA (1)	UA100836C2 (da)
WO (1)	WO2006089690A1 (da)
ZA (1)	ZA200706078B (da)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
UA100836C2 (ru)	2005-02-23	2013-02-11	Бавариан Нордик А/С	Применение модифицированного вируса осповакцины анкара (mva) для быстрой индукции иммунитета против поксвирусных или других инфекционных агентов
US10183986B2 (en)	2005-12-15	2019-01-22	Industrial Technology Research Institute	Trimeric collagen scaffold antibodies
DK2596801T3 (da)	2006-10-06	2018-08-13	Bavarian Nordic As	Rekombinant modificeret vaccinia ankara-virus, der koder for et her-2-antigen, til anvendelse til behandling af cancer
US8268327B2 (en)	2007-04-27	2012-09-18	Bavarian Nordic A/S	Immediate protection against pathogens via MVA
EP2111869A1 (en)	2008-04-23	2009-10-28	Stichting Sanquin Bloedvoorziening	Compositions and methods to enhance the immune system
KR102269491B1 (ko) *	2013-03-15	2021-06-25	버베리안 노딕 에이/에스	단회 고용량의 mva가 신생아 및 영아에서 보호 면역 반응을 유도
US10653766B2 (en)	2014-03-12	2020-05-19	Bavarian Nordic A/S	Use of oil and water emulsions for increasing B cell responses with modified Vaccinia Ankara virus
FR3042121A1 (fr)	2015-10-08	2017-04-14	Jean-Marc Limacher	Composition anti-tumorale
FR3160186A1 (fr)	2024-03-13	2025-09-19	Odimma Therapeutics	Vecteur non-viral pour transcription augmentee

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BR0015491A (pt) *	1999-11-12	2002-10-15	Oncolytics Biotech Inc	Métodos para tratar um distúrbio proliferativo celular mediado por ras em um mamìfero, para tratar um neoplasma tendo uma via-ras ativada em um humano, para inibir metástase de um neoplasma tendo uma via-ras ativada em um mamìfero, e para tratar um neoplasma suspeito de ter uma via-ras ativada em um mamìfero, composição farmacêutica, kit, e, método para tratar uma população de células compreendendo um neoplasma suspeito de ter uma via-ras ativada in vitro
US7097842B2 (en) *	2000-11-23	2006-08-29	Bavarian Nordic A/S	Modified vaccinia virus ankara for the vaccination of neonates
UA76731C2 (uk) *	2000-11-23	2006-09-15	Баваріан Нордік А/С	Штам mva-bn модифікованого вірусу коров'ячої віспи ankara, фармацевтична композиція, вакцина, застосування mva-bn для приготування лікарського препарату та для приготування вакцини, спосіб введення гомологічної і/або гетерологічної послідовності нуклеїнової кислоти в клітини-мішені in vitro, спосіб одержання пептиду або білка, спосіб одержання mva-bn, клітина, набір для основної/бустерної імунізації
CN100540051C (zh)	2002-04-19	2009-09-16	巴法里安诺迪克有限公司	用于接种新生儿的改良的安卡拉痘苗病毒
ATE315660T1 (de) *	2002-05-16	2006-02-15	Bavarian Nordic As	Intergene regionen als insertionsstellen im genom von modifiziertem vaccinia virus ankara (mva)
ES2305514T5 (es) †	2002-09-05	2019-06-14	Bavarian Nordic As	Método para la amplificación de un poxvirus en condiciones exentas de suero
CA2511625A1 (en) *	2002-12-23	2004-07-15	City Of Hope	Modified vaccinia ankara expressing p53 in cancer immunotherapy
US6960345B2 (en) *	2003-03-06	2005-11-01	Incell Corporation, Llc	Oral vaccinia formulation
EP2363143A3 (en) *	2003-03-28	2012-02-15	The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services	MVA expressing modified hiv envelope, gag, and pol genes
UA100836C2 (ru) *	2005-02-23	2013-02-11	Бавариан Нордик А/С	Применение модифицированного вируса осповакцины анкара (mva) для быстрой индукции иммунитета против поксвирусных или других инфекционных агентов
US8268327B2 (en)	2007-04-27	2012-09-18	Bavarian Nordic A/S	Immediate protection against pathogens via MVA

2006
- 2006-02-17 UA UAA200710500A patent/UA100836C2/ru unknown
- 2006-02-17 PT PT67070391T patent/PT1855720T/pt unknown
- 2006-02-17 AU AU2006218115A patent/AU2006218115B2/en not_active Expired
- 2006-02-17 MX MX2007010158A patent/MX2007010158A/es active IP Right Grant
- 2006-02-17 LT LTEP06707039.1T patent/LT1855720T/lt unknown
- 2006-02-17 FI FIEP06707039.1T patent/FI1855720T4/fi active
- 2006-02-17 CN CN2006800058754A patent/CN101128217B/zh not_active Expired - Lifetime
- 2006-02-17 EA EA200701801A patent/EA013404B1/ru not_active IP Right Cessation
- 2006-02-17 DK DK06707039.1T patent/DK1855720T4/da active
- 2006-02-17 SI SI200632128T patent/SI1855720T2/sl unknown
- 2006-02-17 CA CA2593532A patent/CA2593532C/en not_active Expired - Lifetime
- 2006-02-17 WO PCT/EP2006/001447 patent/WO2006089690A1/en not_active Ceased
- 2006-02-17 KR KR1020077017385A patent/KR20070110007A/ko not_active Ceased
- 2006-02-17 ES ES06707039T patent/ES2608627T5/es not_active Expired - Lifetime
- 2006-02-17 HU HUE06707039A patent/HUE030037T2/en unknown
- 2006-02-17 NO NO20074855A patent/NO347468B1/no unknown
- 2006-02-17 EP EP06707039.1A patent/EP1855720B2/en not_active Expired - Lifetime
- 2006-02-17 BR BRPI0608310-2A patent/BRPI0608310A2/pt not_active Application Discontinuation
- 2006-02-17 JP JP2007555533A patent/JP2008531489A/ja active Pending
- 2006-02-17 NZ NZ556409A patent/NZ556409A/en not_active IP Right Cessation
- 2006-07-20 MY MYPI20063481A patent/MY162027A/en unknown
2007
- 2007-07-02 IL IL184347A patent/IL184347A/en active IP Right Grant
- 2007-07-23 ZA ZA2007/06078A patent/ZA200706078B/en unknown
- 2007-08-23 US US11/892,479 patent/US20110142877A1/en not_active Abandoned
2011
- 2011-12-22 US US13/335,097 patent/US8808709B2/en active Active
2012
- 2012-07-10 JP JP2012154752A patent/JP5952112B2/ja not_active Expired - Lifetime
2014
- 2014-07-10 US US14/328,474 patent/US9265823B2/en not_active Expired - Lifetime
2016
- 2016-03-03 JP JP2016041014A patent/JP2016104822A/ja active Pending
- 2016-12-22 CY CY20161101335T patent/CY1118573T1/el unknown

Also Published As

Publication number	Publication date
MY162027A (en)	2017-05-31
IL184347A0 (en)	2007-10-31
PT1855720T (pt)	2016-12-14
JP2008531489A (ja)	2008-08-14
CN101128217B (zh)	2012-04-25
WO2006089690A9 (en)	2012-10-04
FI1855720T4 (fi)	2023-08-31
JP5952112B2 (ja)	2016-07-13
WO2006089690A1 (en)	2006-08-31
UA100836C2 (ru)	2013-02-11
EA200701801A1 (ru)	2008-02-28
KR20070110007A (ko)	2007-11-15
CN101128217A (zh)	2008-02-20
LT1855720T (lt)	2017-01-10
US8808709B2 (en)	2014-08-19
JP2016104822A (ja)	2016-06-09
US9265823B2 (en)	2016-02-23
ES2608627T5 (es)	2023-10-04
NZ556409A (en)	2010-09-30
EP1855720B2 (en)	2023-04-26
DK1855720T4 (da)	2023-07-24
NO20074855L (no)	2007-10-26
US20140341946A1 (en)	2014-11-20
ES2608627T3 (es)	2017-04-12
BRPI0608310A2 (pt)	2009-12-08
CA2593532A1 (en)	2006-08-31
MX2007010158A (es)	2007-10-16
IL184347A (en)	2016-07-31
SI1855720T2 (sl)	2023-07-31
ZA200706078B (en)	2012-10-31
NO347468B1 (no)	2023-11-13
EP1855720A1 (en)	2007-11-21
SI1855720T1 (sl)	2017-01-31
CA2593532C (en)	2017-05-02
CY1118573T1 (el)	2017-07-12
EA013404B1 (ru)	2010-04-30
JP2012193198A (ja)	2012-10-11
HK1113466A1 (en)	2008-10-03
AU2006218115A1 (en)	2006-08-31
HUE030037T2 (en)	2017-04-28
US20120107359A1 (en)	2012-05-03
AU2006218115B2 (en)	2012-08-02
EP1855720B1 (en)	2016-10-05
US20110142877A1 (en)	2011-06-16

Publication	Publication Date	Title
BRPI0816147A2 (pt)	2015-02-18	Elemento de fusão intercorporal espinhal.
DK2205731T3 (da)	2013-03-11	Anvendelse og fremstilling af citrat-stabile, neutrale metalloproteaser
DK1931350T3 (da)	2014-02-10	Administration af inhibitorer af dipeptidylpeptidase
CY2016005I2 (el)	2016-08-31	Αλκαλικη φωσφαταση στοχευμενη στα οστα, κιτ και μεθοδοι χρησης αυτων
DK2220076T5 (da)	2012-09-17	Inhibitorer af replikationen af humant immundefektvirus
DK1877232T3 (da)	2014-08-11	Fremgangsmåde til behandling af træoverflader
DK2010498T3 (da)	2011-02-14	Syntese af acylaminoalkenylenamider, der kan anvendes som substans P-antagonister
DK3296284T3 (da)	2022-02-28	Ikke-terapeutisk anvendelse af hydroxybutyratester
DK2019825T3 (da)	2010-11-22	Inhibitorer af human immundefektvirus-replikation
BRPI0717471A2 (pt)	2014-03-11	Dispositivo de entrada
DK2317851T3 (da)	2014-04-14	Anvendelse af 5-fluorcytosin som fungicid
DK2099302T3 (da)	2013-07-29	Antimikrobiel sammensætning til appretering af tekstiler
EP2127251A4 (en)	2015-03-11	PROPAGATION OF KNOWLEDGE OF CONFLICT
BRPI0915134A2 (pt)	2016-02-16	composto, e, uso de um composto
DE502007000290D1 (de)	2009-01-29	Neue Verwendungen von Nonenolid
DK2111555T3 (da)	2013-09-02	Diagnosticering af præeklampsi
BRPI0909880A2 (pt)	2018-02-27	composição adesiva sensível à pressão
EP2053369A4 (en)	2012-03-28	COMBINATION SCALE
FR2901817B1 (fr)	2015-03-27	Pont temporaire
EP2196784A4 (en)	2011-06-01	COMBINATION SCALE
DK2373652T3 (da)	2014-01-20	Substituerede piperidin-spiro-pyrrolidinon- og piperidinon-forbindelser anvendt som h3-modulatorer
DE602007009260D1 (de)	2010-10-28	Zwischenhülse
BRPI0906630A2 (pt)	2015-07-14	Emplastro adesivo
DK2004815T3 (da)	2013-12-02	Funktional ekspression af triacylglycerol-lipaser
DK1855720T3 (da)	2017-01-16	Anvendelse af et modificeret poxvirus til hurtig induktion af immunitet mod et poxvirus eller andre smitstoffer